City

Clinical trials near Luoyang, China

Active studies with a listed research site in Luoyang, China.

20active studies

9recruiting now

14countries represented

195largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Obesity, OverweightCondition

Enicepatide, PlaceboTreatment

China18 locations

Hoffmann-La RocheSponsor

Updated 2026-08-13 · NCT07670416See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowNot applicable

Mobile Applet for Weight Management in Obese Heart Failure Patients

Heart Failure, Overweight and ObesityCondition

Full usage of diet management app group and with the full usage of an intelligent weight scale, Limited usage of diet management app group and with the limited usage of an intelligent weight scaleTreatment

China26 locations

Heart Health Research CenterSponsor

Updated 2025-06-27 · NCT06455878See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonPhase 1

An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese Participants

Overweight, ObesityCondition

IBI3042, PlaceboTreatment

China1 locations

Hongwei JiangSponsor

Updated 2026-09-03 · NCT07802899See eligibility →

Opening soonNot applicable

Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial

Hypertension (HTN)Condition

Empagliflozin and Finerenone, Placebo for Empagliflozin and FinerenoneTreatment

China2 locations

Heart Health Research CenterSponsor

Updated 2026-07-01 · NCT07678151See eligibility →

Opening soonNot applicable

Probiotic for Weight Management in Overweight and Obese Adults

ObesityCondition

Probiotic, PlaceboTreatment

China1 locations

Wecare Probiotics Co., Ltd.Sponsor

Updated 2026-04-02 · NCT07507929See eligibility →

Opening soonPhase 3

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

ObesityCondition

TQF3510 (Semaglutide Injection), Wegovy®Treatment

China66 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2024-12-18 · NCT06738979See eligibility →

Opening soonPhase 3

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

ObesityCondition

Semaglutide, SemaglutideTreatment

China14 locations

Hangzhou Jiuyuan Gene Engineering Co. Ltd.,Sponsor

Updated 2024-10-09 · NCT06633783See eligibility →

Opening soonPhase 2

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

Obesity, Overweight and ObesityCondition

MDR-001, PlaceboTreatment

China19 locations

MindRank AI LtdSponsor

Updated 2024-09-24 · NCT06606483See eligibility →

Active, not recruitingPhase 2

Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity

Overweight , ObesityCondition

MWN109 1, MWN109 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-04 · NCT07804797See eligibility →

Active, not recruitingPhase 2

Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight

Overweight , ObesityCondition

MWN109 1, MWN109 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-08-28 · NCT07791537See eligibility →

Active, not recruitingPhase 3

A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

Overweight , ObesityCondition

Zovaglutide dose 1, Zovaglutide dose 2Treatment

China45 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-08-03 · NCT07230119See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of ZT006 in Overweight and Obese Participants

Overweight , ObesityCondition

ZT006, Placebo of ZT006Treatment

China12 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-06-12 · NCT07230132See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Luoyang, China

Current studies

Related cities